Log in to save to my catalogue

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failur...

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failur...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8169183efd244c82bda9348fe3369e9a

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels

About this item

Full title

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels

Publisher

United States: John Wiley & Sons, Inc

Journal title

Cancer medicine (Malden, MA), 2022-01, Vol.11 (1), p.104-116

Language

English

Formats

Publication information

Publisher

United States: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Background and Aims
Regorafenib has demonstrated its survival benefit for unresectable hepatocellular carcinoma (uHCC) patients in a phase III clinical trial. We aimed to assess the efficacy and tolerability of regorafenib and the predictors of treatment outcomes in Taiwanese patients.
Methods
We analyzed the survival, best overall respons...

Alternative Titles

Full title

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_8169183efd244c82bda9348fe3369e9a

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8169183efd244c82bda9348fe3369e9a

Other Identifiers

ISSN

2045-7634

E-ISSN

2045-7634

DOI

10.1002/cam4.4430

How to access this item